Controversies in the treatment of idiopathic membranous nephropathy

Nature Reviews Nephrology

Volumn 5, Issue 8, 2009, Pages 469-479

  Waldman, Meryl ^a   Austin Iii, Howard A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CORTICOTROPIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ADULT RESPIRATORY DISTRESS SYNDROME; ANGIONEUROTIC EDEMA; BONE MARROW SUPPRESSION; BRONCHOSPASM; CARDIOVASCULAR RISK; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEVER; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; IDIOPATHIC MEMBRANE NEPHROPATHY; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IDOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MORBIDITY; MORTALITY; OPTIMAL DRUG DOSE; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; PRURITUS; RASH; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UREMIA;

DISEASE PROGRESSION; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; RECURRENCE; REMISSION INDUCTION;

EID: 70349303518     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.101     Document Type: Review

References (94)

1. Schena, F. P. survey of the italian registry of renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The italian Group of renal immunopathology. Nephrol. Dial. Transplant. 12, 418-426 (1997).
2. Haas, M., Meehan, S. M., Karrison, T. G. & Spargo, B. H. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am. J. Kidney Dis. 30, 621-631 (1997).
3. Glassock, r. J. secondary membranous glomerulonephritis. Nephrol. Dial. Transplant. 7 (Suppl. 1), 64-71 (1992).
4. Cattran, D. Management of membranous nephropathy: when and what for treatment. J. Am. Soc. Nephrol. 16, 1188-1194 (2005).
5. Passerini, P. & Ponticelli, C. Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy. Semin. Nephrol. 23, 355-361 (2003)
6. du Buf-vereijken, P. w., Branten, A. J. & wetzels, J. F. idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am. J. Kidney Dis. 46, 1012-1029 (2005).
7. [No authors listed] A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative study of the Adult idiopathic Nephrotic syndrome. N. Engl. J. Med. 301, 1301-1306 (1979).
8. Donadio, J. V. Jr et al. idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. 33, 708-715 (1988).
9. Cattran, D. C. et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N. Engl. J. Med. 320, 210-215 (1989).
10. Cameron, J. s., Healy, M. J. & Adu, D. The Medical research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MrC Glomerulonephritis working Party. Q. J. Med. 74, 133-156 (1990).
11. Cattran, D. C., Pei, Y. & Greenwood, C. Predicting progression in membranous glomerulonephritis. Nephrol. Dial. Transplant. 7 (Suppl. 1), 48-52 (1992).
12. Schieppati, A. et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N. Engl. J. Med. 329, 85-89 (1993).
13. Ponticelli, C. et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 48, 1600-1604 (1995)
14. Hogan, s. L., Muller, K. e., Jennette, J. C. & Falk, r. J. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am. J. Kidney Dis. 25, 862-875 (1995).
15. Moranne, O., watier, L., rossert, J. & stengel, B. Primary glomerulonephritis: an update on renal survival and determinants of progression. QJM 101, 215-224 (2008).
16. Bellomo, R. & Atkins, R. C. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 63, 249-254 (1993).
17. Ordonez, J. D., Hiatt, r. A., Killebrew, e. J. & Fireman, B. H. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 44, 638-642 (1993).
18. Branten, A. J. et al. Urinary excretion of β2-microglobulin and igG predict prognosis in idiopathic membranous nephropathy: a validation study. J. Am. Soc. Nephrol. 16, 169-174 (2005).
19. Bazzi, C. et al. Urinary excretion of igG and α(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am. J. Kidney Dis. 38, 240-248 (2001).
20. Cattran, D. C. et al. validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 51, 901-907 (1997).
21. Pei, Y., Cattran, D. & Greenwood, C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. 42, 960-966 (1992).
22. Branten, A. J., reichert, L. J., Koene, r. A. & wetzels, J. F. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM 91, 359-366 (1998).
23. du Buf-vereijken, P. w., Branten, A. J., wetzels, J. F. & Membranous Nephropathy study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol. Dial. Transplant. 19, 1142-1148 (2004).
24. Hofstra, J. M., Branten, A. J. w. & wetzels, J. F. M. No benefit of early start of immunosuppressive therapy in idiopathic membranous nephropathy [abstract]. J. Am. Soc. Nephrol. 19, 60A (2008).
25. Black, D. A., rose, G. & Brewer, D. B. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br. Med. J. 3, 421-426 (1970).
26. Perna, A. et al. immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am. J. Kidney Dis. 44, 385-401 (2004).
27. Ponticelli, C. et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N. Engl. J. Med. 320, 8-13 (1989).
28. Ponticelli, C. et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N. Engl. J. Med. 310, 946-950 (1984)
29. Jha, v. et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 18, 1899-1904 (2007)
30. Reichert, L. J., Huysmans, F. T., Assmann, K., Koene, R. A. & Wetzels, J. F. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann. Intern. Med. 121, 328-333 (1994).
31. Ponticelli, C., Zucchelli, P., Passerini, P. & Cesana, B. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The italian idiopathic Membranous Nephropathy Treatment study Group. N. Engl. J. Med. 327, 599-603 (1992).
32. Ponticelli, C. et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 9, 444-450 (1998).
33. Falk, R. J., Hogan, S. L., Muller, K. E. & Jennette, J. C. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann. Intern. Med. 116, 438-445 (1992).
34. Branten, A. J. & Wetzels, J. F. short-and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. study Group. Clin. Nephrol. 56, 1-9 (2001).
35. Jindal, K., West, M., Bear, R. & Goldstein, M. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am. J. Kidney Dis. 19, 61-67 (1992)
36. west, M. L., Jindal, K. K., Bear, R. A. & Goldstein, M. B. A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis. Kidney Int. 32, 579-584 (1987).
37. Bruns, F. J., Adler, s., Fraley, D. s. & segel, D. P. sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann. Intern. Med. 114, 725-730 (1991).
38. Faurschou, M. et al. Malignancies in wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J. Rheumatol. 35, 100-105 (2008).
39. Hoffman, G. s. et al. wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116, 488-498 (1992).
40. Cattran, D. C. et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 59, 1484-1490 (2001).
41. Cattran, D. C. et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis study Group. Kidney Int. 47, 1130-1135 (1995).
42. Rostoker, G. et al. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 63, 335-341 (1993).
43. Fritsche, L. et al. Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? Nephrol. Dial. Transplant. 14, 1036-1038 (1999).
44. AmbalavanAn, S., Fauvel, J. P., Sibley, R. K. & Myers, B. D. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J. Am. Soc. Nephrol. 7, 290-298 (1996).
45. Guasch, A., Suranyi, M., Newton, L., Hall, B. M. & Myers, B. D. Short-term responsiveness of membranous glomerulopathy to cyclosporine. Am. J. Kidney Dis. 20, 472-481 (1992).
46. Desanto, N. G., Capodicasa, G. & Giordano, C. Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. Am. J. Nephrol. 7, 74-76 (1987).
47. Yao, X. et al. Cyclosporin A treatment for idiopathic membranous nephropathy. Chin. Med. J. (Engl.) 114, 1305-1308 (2001).
48. Goumenos, D. S. et al. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am. J. Nephrol. 27, 226-231 (2007)
49. Goumenos, D. S., Kalliakmani, P., Tsakas, S., Sotsiou, F. & Vlachojannis, J. G. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin. Nephrol. 61, 17-24 (2004)
50. Alexopoulos, e., Papagianni, A., Tsamelashvili, M., Leontsini, M. & Memmos, D. induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol. Dial. Transplant. 21, 3127-3132 (2006).
51. Goumenos, D. S. What have we learned from the use of ciclosporin A in the treatment of nephrotic patients with idiopathic membranous nephropathy? Expert Opin. Pharmacother. 9, 1695-1704 (2008)
52. Cattran, D. C. et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 72, 1429-1447 (2007).
53. Praga, M., Barrio, v., Juárez, G. F., Luño, J. & Grupo español de estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 71, 924-930 (2007).
54. Ballarin, J. et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol. Dial. Transplant. 22, 3196-3201 (2007).
55. Li, X. et al. early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria. J. Nephrol. 21, 584-591 (2008).
56. Jardine, A. G. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl. Int. 18, 379-384 (2005).
57. Artz, M. A. et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am. J. Transplant. 4, 937-945 (2004).
58. Knoll, G. A. & Bell, R. C. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 318, 1104-1107 (1999).
59. Ponticelli, C. & Villa, M. Does cyclosporin have a role in the treatment of membranous nephropathy? Nephrol. Dial. Transplant. 14, 23-25 (1999).
60. Miller, G., Zimmerman, R. 3rd, Radhakrishnan, J. & Appel, G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am. J. Kidney Dis. 36, 250-256 (2000).
61. Choi, M. J. et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 61, 1098-1114 (2002).
62. Polenakovic, M., Grcevska, L. & Dzikova, s. Mycophenolate mofetil in treatment of idiopathic stages iii-iv membranous nephropathy. Nephrol. Dial. Transplant. 18, 1233-1234 (2003).
63. Sahin, G. M., Sahin, S., Kantarci, G. & Ergin, H. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology (Carlton) 12, 285-288 (2007)
64. Senthil Nayagam, L. et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol. Dial. Transplant. 23, 1926-1930 (2008).
65. Segarra, A. et al. Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis--a multicenter study. Nephrol. Dial. Transplant. 22, 1351-1360 (2007).
66. Chan, T. M. et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 12, 576-581 (2007).
67. Branten, A. J., Du Buf-Vereijken, P. W., Vervloet, M. & Wetzels, J. F. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am. J. Kidney Dis. 50, 248-256 (2007).
68. Dussol, B. et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am. J. Kidney Dis. 52, 699-705 (2008).
69. Chan, T. M. et al. efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology study Group. N. Engl. J. Med. 343, 1156-1162 (2000).
70. Rivera, T. L. Current therapies for lupus nephritis in an ethnically heterogeneous cohort. J. Rheumatol. 36, 298-305 (2009).
71. Yau, W. P., Vathsala, A., Lou, H. X. & Chan, E. Is a standard fixed dose of mycophenolate mofetil ideal for all patients? Nephrol. Dial. Transplant. 22, 3638-3645 (2007).
72. Shiiki, H. et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 65, 1400-1407 (2004)
73. Baker, L. r., Tucker, B., Macdougall, i. C. & Oommen, r. Treatment of progressive renal failure and nephrotic syndrome with azathioprine and prednisolone. Postgrad. Med. J. 73, 647-648 (1997).
74. Brown, J. H. et al. Treatment of renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone. Nephrol. Dial. Transplant. 13, 443-448 (1998)
75. Williams, P. S. & Bone, J. M. immunosuppression can arrest progressive renal failure due to idiopathic membranous glomerulonephritis. Nephrol. Dial. Transplant. 4, 181-186 (1989)
76. Goumenos, D. S., Ahuja, M., Davlouros, P., El Nahas, A. M. & Brown, C. B. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study. Clin. Nephrol. 65, 317-323, (2006).
77. Remuzzi, G. et al. Rituximab for idiopathic membranous nephropathy. Lancet 360, 923-924 (2002).
78. Ruggenenti, P. et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J. Am. Soc. Nephrol. 14, 1851-1857 (2003).
79. Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213-1224 (2008).
80. Fervenza, F. C. et al. rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 73, 117-125 (2008).
81. Cravedi, P., ruggenenti, P., sghirlanzoni, M. C. & remuzzi, G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2, 932-937 (2007).
82. Ruggenenti, P. et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin. J. Am. Soc. Nephrol. 1, 738-748 (2006).
83. Cobo, M., Hernández, D., Rodriguez, C. & Pérez- Tamajón, L. successful therapeutic use of rituximab in refractory membranous glomerulonephritis. Clin. Nephrol. 66, 54-57 (2006).
84. Ruggenenti, P. et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin. J. Am. Soc. Nephrol. 3, 1652-1659 (2008).
85. Garjau, M. et al. efficacy of combined therapy with rituximab and tacrolimus in the induction of stable remission of proteinuria in patients with primary membranous glomerulonephritis [abstract]. J. Am. Soc. Nephrol. 19, 561A (2008).
86. Berg, A. L., Nilsson-ehle, P. & Arnadottir, M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 56, 1534-1543 (1999).
87. Berg, A. L. & Arnadottir, M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol. Dial. Transplant. 19, 1305-1307 (2004).
88. Picardi, L. et al. ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. Clin. Nephrol. 62, 403-404 (2004).
89. Ponticelli, C. et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am. J. Kidney Dis. 47, 233-240 (2006).
90. Austin, H. A., Braun, M. J., Howard, L. v., Kopp, J. B. & Balow, J. B. sirolimus therapy in idiopathic and lupus membranous nephropathy [abstract]. J. Am. Soc. Nephrol. 19, 561A (2008).
91. Fervenza, F. C. et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol. Dial. Transplant. 19, 1288-1292 (2004).
92. Debiec, H. et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 346, 2053-2060 (2002).
93. Ronco, P. & Debiec, H. Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men. Semin. Immunopathol. 29, 445-458 (2007).
94. Beck, L. et al. Discovery of the phospholipase A2 receptor as the target antigen in idiopathic membranous nephropathy [abstract]. J. Am. Soc. Nephrol. 19, 104A (2008).